Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 101 of 101 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/01/21
End: 01/31/23
Due: 01/31/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC | NCT04514835 | The First Affiliated Hospital of Zhengzhou University | user2@example.com | None | 2021-12-01 | 2023-01-31 | 2024-01-31 | - | - | 2025-07-14 |